Kenpaullone inhibits KLF4 by suppressing CDK1/cyclin B and GSK-3β, reducing proliferation and migration of breast cancer cells in canine mammary cancer and inducing cancer cell death, although its effects in humans require further investigation (163). Here, KLF4 is linked to cancer.